Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-24
2009-08-18
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S086000, C436S501000, C435S007900, C530S300000, C530S387900, C600S300000, C702S019000, C702S023000
Reexamination Certificate
active
07575876
ABSTRACT:
The present invention provides methods for diagnosing neurodegenerative disease, such as Alzheimer's Disease, Parkinson's Disease, and dementia with Lewy body disease by detecting a pattern of gene product expression in a cerebrospinal fluid sample and comparing the pattern of gene product expression from the sample to a library of gene product expression pattern known to be indicative of the presence or absence of a neurodegenerative disease. The methods also provide for monitoring neurodegenerative disease progression and assessing the effects of therapeutic treatment. Also provided are kits, systems and devices for practicing the subject methods.
REFERENCES:
Blennow, Journal of Internal Medicine 256:224-234, Sep. 2004.
Earley et al., Cytometry 50(5): 239-42, Oct. 15, 2002.
Otto et al., Methods, 44: 289-298 (2008).
Hickey et al., Current Alzheimer Research, 5:52-60, 2008.
Bacskai et al., “Imaging Amyloid-β Deposits In Vivo”, J Cereb Blood Flow Metab, 2002. 22(9): p. 1035-41.
Klunk et al., “Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton and Methoxy-X04, a Systemically Administered Congo Red Derivative”, J Neuropathol Exp Neurol, 2002. 61(9): p. 797-805.
Small et al., “In Vivo Brain Imaging of Tangle Burden in Humans”, J Mol Neurosci, 2002. 19(3): p. 323.
Jankovic et al., “The Evolution of Diagnosis in Early Parkinson Disease”, Arch Neurol, 2000. 57(3): p. 369.
Hughes et al., “The accuracy of Diagnosis of Parkinsonian Syndromes in a Specialist Movement Disorder Service”, Brain, 2002. 125(Pt 4): p. 861.
Litvan et al., “Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia with Lewy Bodies”, Arch Neurol, 1998. 55(7): p. 969.
Rajput et al., “Accuracy of Clinical Diagnosis in Parkinsonism—A Prospective Study”, Can J Neurol Sci, 1991. 18(3): p. 275.
Hughes et al., “Accuracy of Clinical Diagnosis of Idiopathic Parkinson's Disease: a clinico-Pathological Study of 100 Cases”, J Neurol Neurosurg Psychiatry, 1992. 55(3): p. 181-184.
McKeith et al., “Dementia with Lewy Bodies”, Semin Clin Neuropsychiatry, 2003. 8(1): p. 46.
Love et al., “Post Mortem Sampling of the Brain and other Tissues in Neurodegenerative Disease”, Histopathology, 2004. 44(4): p. 309.
Olsson et al., “Simultaneous Measurement of β-Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology”, Clin Chem, 2005. 51(2): p. 336.
Zhang et al., “Quantitative Proteomic Analysis of Age-Related Changes in Human Cerebrospinal Fuid”, Neurobiol Aging, 2005. 26(2): p. 207.
Zhang et al., “Quantitative Proteomic of Cerebrospinal Fluid from Patients with Alzheirmer Disease”, J Alzheimers Dis, 2005. 7(2): p. 125.
Baba Edward J.
Bozicevic Field & Francis LLP
Chernyshev Olga N
MacFarlane Stacey
The University of Washington
LandOfFree
Biomarkers for neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054642